Sales of Pfizer’s COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61%.
The coronavirus vaccine Comirnaty brought in more than $13 billion in sales, and the treatment Paxlovid added another $1.5 billion as company revenue swelled 77%, the company said Tuesday.
Pfizer posted adjusted earnings of $1.62 per share in the first quarter, on $25.66 billion in revenue.
Analysts expected per-share earnings of $1.49 on about $24.1 billion in sales, according to FactSet.
Pfizer Inc., based in New York, also revised its 2022 earnings forecast to reflect an accounting policy change. It now expects adjusted earnings of $6.25 to $6.45 per share.
That’s down from its previous forecast for $6.35 to $6.55 per share.
Analysts forecast earnings of $7.14 per share.
Shares ticked slightly higher before the opening bell Thursday.
Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.